
Launch of respiratory test panel



"Novacyt has established itself as a pioneer in COVID-19 diagnostics through the rapid development and success of its COVID-19 PCR test and the launch of Winterplex™ is another example of this innovative approach. We believe Winterplex™ is one of the world's first approved respiratory test panels that can differentiate between COVID-19 and other common respiratory diseases. The test panel is a key addition to our COVID-19 product portfolio to support healthcare providers as we approach flu season in the Northern hemisphere."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. - End -Contacts Novacyt SA Graham Mullis, Chief Executive Officer Anthony Dyer, Chief Financial Officer +44 (0)1276 600081 SP Angel Corporate Finance LLP (Nominated Adviser and Broker) Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) +44 (0)20 3470 0470 FTI Consulting (International) Victoria Foster Mitchell / Mary Whittow +44 (0)20 3727 1000 victoria.fostermitchell@fticonsulting.com / mary.whittow@fticonsulting.com FTI Consulting (France) Arnaud de Cheffontaines +33 (0)147 03 69 47 arnaud.decheffontaines@fticonsulting.com

About Novacyt Group

The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.

For more information please refer to the website: www.novacyt.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFFFVLTSIRFII